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TGF-β is essential for vascular development; however, excess TGF-β signaling promotes thoracic aortic aneu-
rysm and dissection in multiple disorders, including Marfan syndrome. Since the pathology of TGF-β over-
activity manifests primarily within the arterial media, it is widely assumed that suppression of TGF-β signal-
ing in vascular smooth muscle cells will ameliorate aortic disease. We tested this hypothesis by conditional 
inactivation of Tgfbr2, which encodes the TGF-β type II receptor, in smooth muscle cells of postweanling mice. 
Surprisingly, the thoracic aorta rapidly thickened, dilated, and dissected in these animals. Tgfbr2 disruption 
predictably decreased canonical Smad signaling, but unexpectedly increased MAPK signaling. Type II recep-
tor–independent effects of TGF-β and pathological responses by nonrecombined smooth muscle cells were 
excluded by serologic neutralization. Aortic disease was caused by a perturbed contractile apparatus in medi-
al cells and growth factor production by adventitial cells, both of which resulted in maladaptive paracrine 
interactions between the vessel wall compartments. Treatment with rapamycin restored a quiescent smooth 
muscle phenotype and prevented dissection. Tgfbr2 disruption in smooth muscle cells also accelerated aneu-
rysm growth in a murine model of Marfan syndrome. Our data indicate that basal TGF-β signaling in smooth 
muscle promotes postnatal aortic wall homeostasis and impedes disease progression.
Introduction
TGF-β, comprising 3 isoforms and acting via a heteromeric com-
plex of TGF-β type I and II receptors (TβRI and TβRII, respectively), 
has pleiotropic effects throughout development (1). Animal models 
allow these effects to be studied longitudinally. Germline deletions 
in mice of Tgfbr1 or Tgfbr2, which encode TβRI and TβRII, cause 
midgestational death due to vascular defects of the yolk sac (2, 3). 
Moreover, selective deletion of Tgfbr1 and Tgfbr2 in smooth muscle 
recapitulates the vascular deformities and embryonic lethality of 
global deletion (4). Even gene deletion restricted to specific smooth 
muscle lineages leads to vascular abnormalities and perinatal death 
(5–7). Although germline genetic modifications have provided 
valuable insight into TGF-β signaling in vascular morphogenesis, 
they are not suitable for studying mechanisms of vascular homeo-
stasis or disease progression that occur postnatally. In humans, 
Loeys-Dietz syndrome, which is caused by heterozygous muta-
tions in TGFBR1 or TGFBR2, often presents in young adults with 
complications of aortic dissection or aneurysm rupture (8). Even 
though the mutant receptors cannot transduce TGF-β–mediated 
signals (9, 10), tissues obtained at surgery paradoxically suggest 
enhanced TGF-β signaling in vivo (8, 11). Excessive TGF-β activity 
is also observed in the media of aortic aneurysms from patients 
with Marfan syndrome caused by mutations of FBN1 (encod-
ing fibrillin-1) as well as in patients with a phenotype similar to 
that seen in Loeys-Dietz and Marfan disorders, which is caused by 
mutations in TGFB2 or SMAD3 (11–13). Similarly, upregulation of 
TGF-β signaling is found in nonsyndromic aortic disease caused 
by mutations in MYH11 (encoding smooth muscle myosin heavy 
chain [SMMHC]) and ACTA2 (encoding SMA) as well as undefined 
etiologies (14, 15). Increased TGF-β activity has been hypothesized 
as resulting from impaired sequestration of latent TGF-β complex-
es in the extracellular matrix by aberrant fibrillin-1 in Marfan syn-
drome (16) and from greater production of TGF-β in the overlap-
ping phenotype due to TGFB2 mutations (12, 13). Increased TGF-β 
signaling associated with aortic disease is inferred from nuclear 
accumulation of phosphorylated Smad2 (p-Smad2), a canonical 
signaling mediator of TGF-β, and increased expression of typical 
TGF-β–inducible molecules in clinical specimens. Similar findings 
of TGF-β overactivity are evident in mouse models of Marfan syn-
drome caused by Fbn1 deletion or mutation (16–18). Treatment of 
these animals with TGF-β antagonists prevents phenotypic mani-
festations of Marfan syndrome (16, 17). Based on these promis-
ing experimental results, clinical trials of losartan, an angiotensin 
receptor blocker that also antagonizes TGF-β signaling, have been 
initiated in patients with Marfan syndrome (19). Yet recent stud-
ies uncovered a more complex relationship in which noncanoni-
cal TGF-β signaling also promotes aneurysm formation in mouse 
models of Marfan syndrome, primarily through MAPK cascades, 
including p38 and ERK1/2 pathways (18, 20). The mechanisms by 
which these perturbations in signaling cause aortic disease remain 
poorly understood, however. In both syndromic and nonsyndromic 
aortic diseases, it is generally believed that pathological effects of 
hyperactive TGF-β signaling are intrinsic to vascular smooth mus-
cle and that suppression of TGF-β responses in this cell type will 
prevent dissection and aneurysm formation. Here, we directly test 
this hypothesis using a genetically defined animal model.
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Results
Conditional disruption of Tgfbr2 in smooth muscle of postnatal mice. We 
investigated whether TGF-β is required for continued integrity of 
the developed vasculature by inactivating TβRII in postweanling 
mice; this receptor is essential for ligand binding and transphos-
phorylation of TβRI (1). To circumvent embryonic lethality, mice 
homozygous for Tgfbr2 in which exon2 was flanked with loxP 
sites (21) were bred with mice expressing Cre recombinase fused 
with a modified estrogen receptor–binding domain (ERT2) under 
control of a smooth muscle–specific Myh11 promoter (22). Dual 
transgene expression allows inducible Cre activity and deletion of 
floxed DNA segments by injection of a synthetic estrogen, tamoxi-
fen. Specificity and efficiency of gene modification were assessed 
by intercrossing to mT/mG double-fluorescent reporter mice 
that ubiquitously express the product of a floxed gene for mem-
brane-targeted Tomato, a variant red fluorescent protein (RFP), 
except where deleted by Cre to express membrane-targeted GFP, 
which marks recombined cells (23). After tamoxifen treatment of 
mT/mG.Myh11-CreERT2.Tgfbr2f/f mice, SMCs selectively and robust-
ly expressed GFP in all segments of the aorta (Figure 1, A and B). 
Recombination of floxed Tgfbr2 alleles was confirmed, although 
unmodified gene sequence was still detected in aortic tissue con-
sisting of several vascular layers and cell types (Figure 1C). Sepa-
ration of the aortic wall into inner muscular and outer fibrous 
layers demonstrated tamoxifen-mediated deletion of Tgfbr2 
within the media (Figure 1D). Correspondingly, TβRII expression 
was markedly decreased in medial tissue (which still contained 
endothelium after removing the adventitia) following tamoxifen 
induction (Figure 1E). GFP+ SMCs were propagated after explant 
growth and flow cytometric sorting to exclude any nonrecom-
bined or contaminating cells, such as fibroblasts (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI69942DS1). Expression of mRNA for Tgfbr2 exon2 
or the encoded TβRII extracellular domain was not detected in 
KO cells (Figure 1, F–H). These data show successful disruption 
of Tgfbr2 in the aortic media of postnatal mice and the ability to 
select bona fide SMCs for in vitro experiments.
Tgfbr2 disruption rapidly results in disease of the thoracic aorta. We 
examined the phenotype of Myh11-CreERT2.Tgfbr2f/f mice after 
tamoxifen treatment. There was rapid development of aortic dis-
section, revealed by mural hematoma on gross examination, in 
a subset of KO animals that progressively increased in incidence 
Figure 1
Conditional disruption of Tgfbr2 in smooth muscle of postnatal mice. (A) Selective expression of GFP and loss of RFP in medial, but not intimal 
or adventitial, cells of mT/mG.Myh11-CreERT2.Tgfbr2f/f mice after vehicle (Veh) or tamoxifen (Tmx) treatment; nuclei stained with DAPI. Scale 
bar: 30 μm. (B) Diffuse Cre-mediated GFP expression in the aortic root, ascending aorta (and adjacent pulmonary artery), and descending 
aorta. Scale bar: 150 μm. (C) Scheme of Tgfbr2 floxed allele and PCR for 420 bp WT, 540 bp floxed (Lox), and 610 bp Cre-deleted (Del) bands 
in abdominal aortas of Tgfbr2WT/f and Myh11-CreERT2.Tgfbr2f/f mice without and with tamoxifen treatment. (D) Tgfbr2 detection in media (Med) 
and adventitia (Adv) from thoracic aortas of Myh11-CreERT2.Tgfbr2f/f mice treated with vehicle or tamoxifen and (E) TβRII expression in the iso-
lated medial tissue. (F) PCR for Tgfbr2 exon2 mRNA expression and (G) immunoblotting and (H) flow cytometric analysis for TβRII extracellular 
domain expression in GFP+ SMCs cultured from thoracic aortas of mT/mG.Myh11-CreERT2 (Cre) and mT/mG.Myh11-CreERT2.Tgfbr2f/f (KO) mice 
after tamoxifen induction.
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with time depending on the age at induction (Figure 2, A and B). 
Younger animals, with a higher incidence of aortic dissection, also 
had more extensive disease (Supplemental Figure 2A). Aortic rup-
ture or unexpected deaths were not observed from 2 to 26 weeks 
after tamoxifen treatment at 4 weeks of age; thus, this induction 
protocol was used for most of the subsequent experiments. Hem-
orrhage of the aortic wall usually began in the proximal ascending 
or proximal descending segments, and occasionally, intimal flaps 
and false lumens were identified (Supplemental Figure 2, A and B). 
The dissections often extended into arch branches, but the abdom-
inal aorta was rarely involved (2 of 180 mutants). Injury of the ves-
sel wall was not due to hypertension, as central blood pressure was 
modestly reduced in KO mice (Figure 2C). Consistent dilatation 
of the ascending aorta was noted by 6 weeks of age irrespective of 
dissection occurrence (Figure 2D). In the presence of dissection, 
mural thickening characterized by elastin fragmentation, elastic 
lamella widening, and adventitial fibrosis evolved between 6 and 
10 weeks (Figure 2E). Leukocytes accumulated in the underlying 
adventitia in association with erythrocyte extravasation into the 
media; acellular medial foci developed by 10 weeks, and medial 
degeneration progressed circumferentially by 30 weeks (Supple-
mental Figure 2, C–F). In the absence of dissection, the aortic wall 
in KO mice displayed few morphological abnormalities with rare 
infiltrating leukocytes up to 10 weeks of age, but medial degenera-
Figure 2
Tgfbr2 disruption in smooth muscle results in aortic thickening, dilatation, and dissection. (A) Gross appearance of ascending (Asc) and descend-
ing (Desc) thoracic aorta (arrows mark mural hematomas) in 8-week-old Myh11-CreERT2.Tgfbr2f/f mice treated with vehicle or tamoxifen for 
5 days starting at 4 weeks of age. (B) Aortic dissection rates at various times after tamoxifen treatment of 4-week-old mice (0/28 after 0 weeks, 
11/39 after 2 weeks, 19/40 after 4 weeks, 4/6 after 6 weeks, and 7/11 weeks after 26 weeks) or at 4 weeks after induction starting at different ages 
(10/13 at 3 weeks, 19/40 at 4 weeks, 3/16 at 6 weeks, 1/9 at 9 weeks, and 0/7 at 18 weeks). ***P < 0.001, χ2 test. (C) Aortic blood pressure of 
6-week-old mice treated with vehicle or tamoxifen at 4 weeks of age; n = 6. *P < 0.05, t test. (D) Representative ultrasound images and ascending 
aorta diameters (blue lines) of 6-week-old mice treated with vehicle or tamoxifen at 4 weeks of age; n = 8. ***P < 0.001, t test. (E) H&E, EVG, and 
trichrome stains of the ascending aorta from 6- and 10-week-old mice treated with vehicle or tamoxifen at 4 weeks of age demonstrating pro-
gressive elastin fragmentation, elastic lamella widening, adventitial fibrosis, and mural thickening. Scale bars: 100 μm. (F) Medial and adventitial 
areas of ascending aortas with or without dissection (Dis) in 8-week-old mice treated with vehicle or tamoxifen at 4 weeks of age and (G) similar 
analysis of descending thoracic aortas; n = 3–12. **P < 0.01, ***P < 0.001, 1-way ANOVA.
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tion and adventitial thickening were apparent by 30 weeks even 
without evidence of mural ecchymosis (Supplemental Figure 3). 
The histological changes in dissected aortas manifested as signifi-
cant medial and adventitial expansion within 4 weeks of induc-
tion (Figure 2, F and G). Adventitial fibrosis was associated with 
increased transcript expression for extracellular matrix molecules 
and TGF-β isoforms in the aortic wall of KO mice (Supplemental 
Figure 4). Global inhibition of TGF-β signaling by serologic neu-
tralization did not alter the rate of aortic dissection, but dimin-
ished adventitial collagen accumulation, prevented adventitial 
thickening, and resulted in several sudden deaths from transmu-
ral aortic bleeding (Supplemental Figure 5). Aortic disease was 
not observed 2 to 4 weeks after heterozygous loss of Tgfbr2 (n = 8). 
Additionally, there was no vascular pathology in tamoxifen-treated 
mT/mG.Myh11-CreERT2 mice lacking Tgfbr2f/f (n = 12) or in Tgfbr2f/f 
mice lacking Myh11-CreERT2 (n = 6), which excluded an artifact of 
the induction strategy.
Loss of TβRII responsiveness diminishes Smad2 signaling. To deter-
mine signaling changes after Tgfbr2 disruption that may drive 
aortic disease, we evaluated canonical and noncanonical TGF-β 
signaling via Smad and MAPK pathways, respectively (18, 20). 
Nondissected thoracic aortas from 6-week-old mice were ana-
lyzed to minimize confounding effects from bleeding, inflam-
mation, and remodeling. Adherent adventitia and endothelium 
were not removed due to technical difficulties and the possibil-
ity of triggering injury-related signaling. Immunoblotting dem-
onstrated decreased p-Smad2 (despite greater Smad2 expres-
sion), but increased p-p38 and p-ERK1/2 in KO aorta (Figure 
3A). Parallel signaling changes of lesser magnitude were seen 
after heterozygous Tgfbr2 disruption (Supplemental Figure 6A). 
Decreased Smad2 phosphorylation and increased ERK1/2 phos-
phorylation were localized to the media of KO aorta (Supplemen-
tal Figure 6B). MAPK activation due to signaling in rare nonre-
combined SMCs or by TβRII-independent effects of TGF-β in KO 
aorta was excluded using neutralizing antibody (Supplemental 
Figure 7). The divergence in Smad and MAPK signaling was fur-
ther investigated in vitro by TGF-β treatment of cultured aortas 
or SMCs. TGF-β1–mediated activation of Smad2 and p38 was 
reduced in KO aorta (TβRII-expressing fibroblasts, endothelial 
cells, or nonrecombined SMCs may have contributed to residual 
signaling), although ERK1/2 responses were not detected even in 
treated aortic tissue from noninduced mice (Figure 3B). A caveat 
is that baseline (untreated) levels of p-p38 and p-ERK1/2 were 
greater in cultured KO aortas in keeping with their prior in vivo 
activation following tamoxifen induction. TβRII inactivation also 
abolished TGF-β1–mediated Smad2 and p38 phosphorylation in 
isolated GFP+ SMCs, whereas ERK1/2 activation was not appar-
ent in treated control or KO cells at the times and doses tested 
(Figure 3C). Similar signaling responses were seen after treatment 
with TGF-β2 and TGF-β3 (Supplemental Figure 8). We confirmed 
that signaling, including that of ERK1/2, was intact in cultured 
SMCs in response to another trophic mediator, IGF1 (Figure 
3D). Our data show that stimulation of Smad2 in aortic media by 
TGF-β under homeostatic conditions is mediated through TβRII 
expressed on SMCs, while p38 and ERK1/2 are activated in the 
absence of TβRII responsiveness in the same cells.
Figure 3
TβRII inactivation reduces canonical Smad signaling, but leads to increased MAPK signaling. (A) Immunoblotting for phosphorylated and total 
Smad2, p38, and ERK1/2 in nondissected thoracic aortas from 6-week-old Myh11-CreERT2.Tgfbr2f/f mice treated with vehicle or tamoxifen at 4 
weeks of age; band densities were normalized to corresponding β-actin bands and expressed as a fraction of a control value, n = 6. **P < 0.01; 
***P < 0.001, t test. (B) Expression of signaling mediators in thoracic aorta segments cultured in serum-free medium for 3 hours and then treated 
with TGF-β1 at 10 ng/ml or vehicle for 1 hour. (C) Expression of signaling mediators in GFP+ SMCs cultured from thoracic aortas of tamoxifen-
induced mT/mG.Myh11-CreERT2 (Cre) and mT/mG.Myh11-CreERT2.Tgfbr2f/f (KO) mice, serum-deprived for 24 hours, and then treated with TGF-β1 
at 1 ng/ml or (D) IGF1 at 100 ng/ml for 0–180 minutes.
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Loss of TGF-β signaling impairs the contractile apparatus of vascular 
smooth muscle. To determine mechanisms of aortic disease after 
TβRII inactivation, we assessed the expression of smooth muscle 
contractile molecules, since many contain TGF-β control elements 
in their promoter regions and their inherited abnormalities may 
predispose to aortic disease (24, 25). Although we found decreased 
transcript expression for Acta2, Tagln, and Myh11 in aorta from 
6-week-old KO mice (Figure 4A), there was variable or no differ-
ence in their protein expression at this early time point (Figure 
4B and Supplemental Figure 9A). Decreased immunolabeling 
for SMA was apparent by 10 and at 30 weeks of age (Figure 4C 
and Supplemental Figure 9B). Given that diminished blood pres-
sure, aortic dilatation, and a subset of aortic dissection by 6 weeks 
preceded consistent changes in contractile protein expression, we 
also assessed the phosphorylation of myosin light chain (MLC) — 
a key regulator of myosin-actin interactions and a known target 
Figure 4
Loss of TGF-β signaling impairs the contractile apparatus of vascular smooth muscle. (A) Quantitative PCR for Acta2, Tagln, Myh11 and (B) immu-
noblots for their encoded products SMA, SM22, and SMMHC in thoracic aortas of 6-week-old Myh11-CreERT2.Tgfbr2f/f mice treated with vehicle or 
tamoxifen at 4 weeks; n = 6. *P < 0.05; **P < 0.01, t test. (C) Immunofluorescence analysis for p-MLC and SMA at 30 weeks. Scale bar: 30 μm. (D) 
Expression of total and p-MLC and p-myosin phosphatase target subunit-1 (MYPT1) at 6 weeks; n = 3. **P < 0.01, t test. (E) Transcript expression 
(fold-change treated/untreated) in GFP+ SMCs cultured from tamoxifen-induced mT/mG.Myh11-CreERT2 (Cre) or mT/mG.Myh11- CreERT2.Tgfbr2f/f 
(KO) mice, serum-deprived for 24 hours, and treated or not with TGF-β1 at 1 ng/ml for 6 hours; n = 3. **P < 0.01; ***P < 0.001, t test. (F) Cultured 
KO SMCs show reduced expression of SMA before treatment and lack of MLC activation after treatment with TGF-β1 at 1 ng/ml for 3 hours. (G) 
Collagen gel disc contraction by embedded SMCs after 72 hours in 10% serum-supplemented medium; n = 3. ***P < 0.001, t test. (H) Aortic dis-
section rate in mice treated or not with the MLC kinase inhibitor, ML-7 at 73 μg/d s.c. constant infusion from 4–6 weeks of age; n = 0/28 (vehicle), 
11/39 (tamoxifen), and 6/8 (tamoxifen+ML-7). *P < 0.05; **P < 0.01; ***P < 0.001, χ2 test. (I) Ascending aorta diameter in these animals at 6 weeks; 
n = 5–8. ***P < 0.001, 1-way ANOVA.
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of TGF-β signaling (26, 27). Strikingly, p-MLC was significantly 
decreased (despite increased MLC expression) early after TβRII 
knockdown, and it persisted long-term (Figure 4, C and D, and 
Supplemental Figure 9B). We further investigated the regulation 
of MLC phosphorylation that is governed by kinases and phos-
phatases. Decreased phosphorylation of myosin phosphatase tar-
get subunit-1 after TβRII inactivation (Figure 4D) was consistent 
with deactivation of this inhibitory component and consequently 
increased myosin phosphatase activity and dephosphorylation 
of MLC (26). Similar findings regarding structural and regula-
tory contractile molecules were also seen in cultured cells. TGF-β 
induced Acta2, Tagln, and Myh11 mRNA expression in control, but 
not KO, SMCs (Figure 4E). KO cells expressed lower basal levels of 
contractile proteins, and the robust phosphorylation of MLC in 
response to TGF-β treatment was prevented by TβRII inactivation 
(Figure 4F). Diminished expression of SMA was associated with 
an irregular rounded appearance of KO cells in culture compared 
with spindle-shaped control cells (Supplemental Figure 10, A–C). 
Decreased contractility of KO SMCs was demonstrated in a colla-
gen gel system (Figure 4G). A pathogenetic role for impaired MLC 
activity was confirmed in vivo by treating KO mice with an MLC 
kinase inhibitor that significantly increased the rate of aortic dis-
section, but not the degree of aortic dilatation (Figure 4, H and I). 
These data are concordant with the clinical phenotype of aortic 
dissection with little to no enlargement of the aorta seen in fami-
lies with mutations of MYLK encoding MLC kinase (28).
Figure 5
Loss of TGF-β signaling induces vascular cell proliferative responses. (A) Immunohistochemistry for BrdU incorporation (brown color, arrows) with 
hematoxylin counter-staining of nuclei in thoracic aortas of 6-week-old Myh11-CreERT2.Tgfbr2f/f mice treated with vehicle or tamoxifen at 4 weeks of 
age. Scale bar: 100 μm, BrdU+ medial cells per cross-section, n = 3, ***P < 0.001, t test. (B) Quantitative RT-PCR for Mki67, Ccna2, and Ccnb2; n = 6, 
**P < 0.01, t test and (C) immunoblotting for total and p-S6K and S6 in thoracic aortas at 6 weeks. (D) Igf1 transcript expression in full-thickness thoracic 
aortas at 6 weeks; n = 6, P < 0.01, t test or in (E) adventitia (Adv) separated from media (arrows) by laser capture microdissection at 10 weeks; n = 3, 
**P < 0.01, ***P < 0.001, 1-way ANOVA. (F) Expression of activated S6K, S6, and ERK1/2 in thoracic aortas of KO mice treated with isotype-matched 
IgG or IGF1 antibody (Ab) at 125 μg/d i.p., q.o.d. from 4–6 weeks or (G) treated with rapamycin (Rapa) at 2 mg/kg/d i.p., q.d. from 3–7 weeks. (H) EVG 
stains with higher magnification of vessel wall shown in insets. Scale bar: 100 μm and (I) diameter of ascending aortas in 7-week-old mice induced 
with vehicle or tamoxifen at 3 weeks of age and treated or not with rapamycin as above; n = 10–11, ***P < 0.001, 1-way ANOVA. (J) Aortic dissection 
rate in these animals; n = 0/11 (vehicle), 10/13 (tamoxifen), and 0/11 (tamoxifen+rapamycin), ***P < 0.001, χ2 test.
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Loss of TGF-β signaling elicits vascular cell proliferation. We searched 
for additional pathogenetic effects of TβRII inactivation, since 
genetic disruption of contractile molecule expression or activity 
in mice does not result in overt aortic dissection or aneurysm phe-
notypes (28–30). We assessed for excessive SMC proliferation, as 
TGF-β has well-described growth regulatory effects (1) and medial 
hyperplasia is associated with certain aortic diseases (31–33). BrdU 
incorporation revealed increased cell division in all layers of the 
aortic wall after loss of TGF-β signaling in smooth muscle, partic-
ularly in the outer media and adventitia (Figure 5A). Cultured KO 
SMCs also displayed increased BrdU incorporation in response to 
serum stimulation (Supplemental Figure 10D). Transcript analy-
sis of KO aortas confirmed increased expression of proliferation 
markers and cell-cycle regulators (Figure 5B). Immunoblotting 
demonstrated greater phosphorylation of mTOR effectors char-
acteristic of mitogenic responses (Figure 5C). However, activation 
of the mTOR pathway, like that of ERK1/2, was unlikely a direct 
effect of TβRII knockdown, as exogenous TGF-β did not suppress 
mTOR signaling of SMCs in vitro, but actually led to phosphory-
lation of mTOR targets in delayed fashion (Supplemental Figure 
11A). To screen for secondary mediators of mTOR activation 
after Tgfbr2 disruption, we performed a genome-wide analysis by 
DNA microarray hybridization of KO versus control aorta. Of 120 
transcripts with altered expression, including numerous prolif-
eration markers and cell cycle regulators (Supplemental Table 1; 
microarray data from this table have also been deposited in the 
Gene Expression Omnibus; GSE36778), we focused on the induc-
tion of IGF1 — a key growth factor related to aneurysm formation 
Figure 6
TβRII inactivation exacerbates mutant fibrillin-1–induced aortic disease. (A) Gross appearance of thoracic aorta (arrow marks dissected aneu-
rysm) in 8-week-old Fbn1C1039G/+.Myh11- CreERT2.Tgfbr2f/f mice treated with vehicle or tamoxifen for 5 days starting at 4 weeks of age. (B) 
Thoracic aortas of 30-week-old Myh11-CreERT2.Tgfbr2f/f (Cre.Tgfbr2) and Fbn1C1039G/+.Myh11- CreERT2.Tgfbr2f/f littermates treated with vehicle 
or tamoxifen. (C) Ascending aorta diameters by serial ultrasound imaging at 10, 20, and 30 weeks; n = 3–4. *P < 0.05, 1-way ANOVA. (D) Repre-
sentative images of aortic root and ascending aorta diameters (blue lines) at 30 weeks. (E) Aortic dissection rates at 8 weeks; n = 0/20 (WT), 0/15 
(mutant Fbn1), 15/32 (Tgfbr2 KO), and 20/22 (compound mutant). ***P < 0.001, χ2 test. (F) Immunoblotting for phosphorylated and total Smad2 
in nondissected aortas at 5 weeks and (G) at 30 weeks. (H) PCR for deleted (del) vs. floxed (lox) Tgfbr2 and WT (+) vs. mutant (C1039G) Fbn1 
in abdominal aorta specimens.
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in inherited abnormalities of smooth muscle contractile proteins 
(33). Increased production of IGF1 after TβRII inactivation was 
confirmed by quantitative techniques (Figure 5D). Using laser cap-
ture microdissection of aortic wall layers, more than 95% of IGF1 
transcription was localized to the adventitia of KO aorta (Figure 
5E). A paracrine role for adventitial-derived IGF1 in smooth mus-
cle mitogenic signaling was verified by its serologic neutralization, 
which reduced mTOR and ERK1/2 activation (Figure 5F). The role 
of SMC proliferation was further investigated using a pharmaco-
logical inhibitor of mTOR signaling. Rapamycin administered at 
2 mg/kg/d, a validated therapeutic dose in other models of arte-
rial disease characterized by SMC hyperplasia (34, 35), resulted in 
whole-blood trough levels of 27.3 ± 5.0 ng/ml (n = 6). This treat-
ment strategy inhibited mTOR and ERK1/2 signaling of KO aorta 
in vivo (Figure 5G). In vitro, rapamycin at 10–100 ng/ml abolished 
IGF1-mediated mTOR, but not ERK1/2 signaling, in cultured KO 
SMCs (Supplemental Figure 11B). Rapamycin did not normalize 
the expression of p-Smad2 after tamoxifen induction (Supple-
mental Figure 12A). Remarkably, however, rapamycin treatment 
completely prevented degeneration, dilatation, and dissection of 
the aorta even under the more stringent conditions of early dis-
ruption of Tgfbr2 at 3 weeks of age (Figure 5, H–J). Prevention of 
aortic disease was associated with diminished expression of prolif-
eration markers and cell-cycle regulators as well as decreased SMC 
hyperplasia and medial expansion, although IGF1 production and 
the expression or activity of contractile molecules was not affected 
(Supplemental Figure 12, B–E). Rapamycin administration also 
did not modulate the number of sparse perivascular leukocytes 
or the absence of medial infiltrates (Supplemental Figure 12F). 
These data suggest that SMC proliferation represents a pathologi-
cal response to loss of TGF-β signaling and is not merely a marker 
for another growth factor–mediated pathogenic process, e.g., SMC 
dedifferentiation, or for an inflammatory effect.
TβRII inactivation exacerbates mutant fibrillin-1–mediated aortic dis-
ease. Finally, we interbred Fbn1C1039G/+ and Myh11-CreERT2.Tgfbr2f/f 
mice to test the hypothesis that aortic disease attributable to 
mutant fibrillin-1 is prevented by inhibition of TGF-β signaling 
in smooth muscle (17, 20). Remarkably, there were more severe 
pathological changes of the aorta in compound mutant mice than 
in those with mutant fibrillin-1 alone (Figure 6, A and B, and Sup-
plemental Figure 13). Serial ultrasound measurements showed 
faster and larger ascending aorta aneurysm formation in com-
pound mutant mice, which approached twice the diameter seen in 
controls by 30 weeks (Figure 6C). Similarly, the aortic root was 1.5 
to 1.9 times larger than that in control or single mutant mice at 
30 weeks (P < 0.01, 1-way ANOVA, n = 3–4). Unlike in Fbn1C1039G/+ 
mice, the ascending aorta was consistently larger than the aortic 
root after Tgfbr2 disruption (Figure 6D). Aortic dissection mani-
fested as early as 5 weeks and was almost uniformly present by 8 
weeks in compound mutant mice (Figure 6E). Immunoblotting of 
nondissected specimens confirmed diminished Smad2 activation 
after TβRII inactivation on WT and mutant Fbn1 backgrounds 
(0.38- and 0.24-fold normalized expression levels, respectively) at 5 
weeks (Figure 6F). These differences were largely lost by 30 weeks, 
and increased phosphorylation of Smad2 in aortas of Fbn1C1039G/+ 
mice (1.7-fold normalized expression levels) was evident at this late 
time point (Figure 6G). Despite more severe pathological changes, 
the abnormalities in signaling, contractile molecules, and prolif-
eration were not greater in compound mutants at either early or 
late time points (Supplemental Figures 14 and 15), although the 
degree of Tgfbr2f/f recombination was not uniform between the 
aortas from WT versus mutant Fbn1 backgrounds (Figure 6H). 
The differences in dissection occurrence, in sites of maximal aneu-
rysmal dilatation, and the lack of correlation between phenotype 
severity and inferred pathogenic events suggest different mecha-
nisms of aortic disease resulting from TβRII inactivation than for 
fibrillin-1 mutation.
Discussion
We conclude (a) that basal TGF-β signaling in smooth muscle is 
required to preserve structural integrity and maintain quiescent 
interactions between medial and adventitial compartments of the 
thoracic aorta following normal embryonic development and (b) 
inactivation of these TβRII-dependent responses in SMCs exac-
erbates aortic disease in a model of Marfan syndrome. Although 
there are similarities in the medial degeneration and aortic dissec-
tion of our animals with human disease (11–15), we do not suggest 
that our strategy of inducible Tgfbr2 deletion in smooth muscle of 
postnatal animals models Loeys-Dietz syndrome attributable to 
heterozygous TGFBR2 point mutations in the germline of patients. 
Mice with analogous Tgfbr2 point mutations will be the optimal 
experimental system to model this disease. The observed pheno-
type in our animals depends strongly on the age at which Tgfbr2 is 
disrupted. Younger mice had a greater incidence of aortic dissec-
tion, suggesting a sensitivity of growing arteries to basal TGF-β 
signaling, not unlike prenatally developing vessels (5–7). Greater 
cellular proliferation and extracellular matrix production distin-
guished both developing and growing aortas from mature ones. 
We speculate that cell division transiently alters SMC contractile 
apparatus and cell-matrix interactions, which may predispose the 
vessel wall to complications of dissection and dilatation. However, 
our studies in older mice terminated at 4 weeks after induction 
were limited, and we cannot exclude delayed onset of disease with 
longer observation periods. The adult aorta with comparatively 
fewer requirements in cellular and extracellular matrix turnover to 
maintain wall integrity may not manifest pathology due to under-
lying genetic predispositions unless subjected to further vascular 
injury or increased hemodynamic loading.
Our conclusions are contingent upon ablation of TGF-β signal-
ing in SMCs after Tgfbr2 disruption. A previous report verified 
no binding of radiolabeled TGF-β1 to TβRI after Cre-mediated 
deletion of Tgfbr2 in fibroblasts (21). We found that both TGF-β–
mediated Smad2 activation and Smad-independent p38 activa-
tion (36) were eliminated after TβRII inactivation in cultured 
SMCs. We did not find immediate activation of ERK1/2 by TGF-β 
in murine SMCs, known to be delayed and to depend on protein 
synthesis in certain cell types (37) and TβRII in cell types with 
rapid activation (38). Our experiments with isolated KO cells in 
vitro and neutralizing antibodies in vivo do not support TβRII-
independent signaling by TGF-β in postnatal SMCs, as recently 
described for embryonic cranial neural crest cells (39). The p38 and 
ERK1/2 activation following TβRII inactivation in vivo is likely an 
indirect effect that results from stress-related and/or growth fac-
tor–mediated responses, since exogenous TGF-β does not directly 
affect MAPK signaling of KO cells in vitro. We show that increased 
ERK1/2 signaling in KO aorta is at least partly due to adventitia-
derived IGF1. It has been previously documented in Fbn1-null 
mice that stress-related MAPK activation can lead to promiscu-
ous Smad2 activation in SMCs independently of TGF-β signaling 
(18) and this crosstalk may also explain apparent normalization of 
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p-Smad2 expression at 30 weeks of age following Tgfbr2 disruption 
besides an increased number of TβRII-responsive adventitial cells 
constituting the degenerated vessel wall at this late time point.
We describe several mechanisms that link loss of TGF-β signal-
ing in smooth muscle to aortic dissection and dilatation. Con-
tractile dysfunction is thought to underlie aortic aneurysm and 
dissection due to MYH11 and ACTA2 mutations in humans (25), 
and dedifferentiation of aortic SMCs harboring TGFBR2 mis-
sense mutations from clinical specimens has been described (10). 
In mice, Myh11 mutation and Acta2 deletion cause a milder phe-
notype characterized by abnormalities in vascular contractility 
without overt aortic disease; additional vascular injury in these 
strains unmasks a gain in proliferative function of SMCs (29, 30). 
Although contractile protein expression gradually and modestly 
declines in our Tgfbr2 KO aortas, the early and robust loss of MLC 
phosphorylation correlates better with the rapid onset of vascu-
lar disease following TβRII inactivation. This conclusion is sup-
ported by clinical findings showing that loss-of-function muta-
tions in MYLK encoding MLC kinase associate with 
aortic dissection (28). Thus, modulating MLC activity, 
either directly or through its kinase and phosphatase 
regulatory enzymes, may have utility in aortic disease 
treatment. However, smooth muscle–specific knock-
down of Mylk in mice causes medial degeneration 
without mural dissection (28) — suggesting coopera-
tive effects of diminished MLC activity with additional 
disease precipitants in our model. Hyperplastic medial 
remodeling was first described in thoracic aortic aneu-
rysms as a compensatory response to increased tensile 
stress or as a driver of vessel growth and expansion (31). 
More recently, hyperplastic vasculomyopathy has been 
reported as a pathological manifestation resulting from 
ACTA2 mutations (32). Moreover, patients with loss-
of-function mutations in TSC2, an inhibitor of mTOR, 
have vascular disease, including aortic aneurysms, and 
SMCs from mice with heterozygous loss of Tsc2 are 
characterized by increased mTOR signaling and prolif-
eration (34). We found that rapamycin prevents aortic 
dissection and dilatation in addition to suppressing 
smooth muscle mitogenesis. The precise benefits of 
rapamycin in this setting require further definition, but 
may relate to effects on SMC cytoskeleton organization 
besides its antiproliferative properties (40). Inhibition 
of mTOR signaling in vascular cells represents what 
we believe is a novel therapeutic approach to prevent-
ing aortic disease, although additional work is required 
to exclude an immunosuppressive effect as the relevant 
mechanism (41, 42). However, a concern against the use 
of cytostatic agents is that fibroblast hyperplasia and 
adventitial thickening contribute to vessel wall integrity 
and may prevent fatal transmural rupture. Nonetheless, 
a gain in proliferative function may be a cause as well as 
a consequence of SMC dedifferentiation. Similarly to 
recent findings by the Milewicz group in Myh11-mutant 
and Acta2-deficient mice (29, 30), we hypothesize that 
altered SMC mechanosensing may link the contractile 
dysfunction, MAPK activation, and medial hyperplasia 
that occur after Tgfbr2 disruption (Figure 7).
Our results highlight the paracrine interactions 
between vascular compartments and the need to con-
sider whole tissues in context (43). In our model, the media is 
the primary site of signaling alterations that are reflected in the 
aortic tissue immunoblots at 6 weeks of age. Within 2 weeks of 
TβRII inactivation, contractile apparatus perturbations are evi-
dent, with consistent changes in blood pressure and blood vessel 
size and partial occurrence of medial dissection. The adventitia, of 
normal appearance at this initial disease stage, undergoes reactive 
changes over several weeks (in the presence of medial dissection) 
to months (in the absence of medial dissection); these changes 
are associated with growth factor production, cellular hyperpla-
sia, and collagen deposition. The majority of the adventitial cells 
appear to be fibroblasts with relatively few SMA-expressing myo-
fibroblasts (44). The reparative responses are ineffective, and the 
media progressively degenerates over 30 weeks. We have identi-
fied IGF1 as one mediator of the trans-compartmental interac-
tion. In a similar system of Tgfbr2 disruption in stromal fibro-
blasts, increased production of hepatocyte growth factor caused 
neoplasia of adjacent epithelia (21). It is likely that several other 
Figure 7
Schematic representation of the essential role for TGF-β in postnatal aortic wall 
homeostasis. Tgfbr2 disruption in SMCs leads to loss of basal Smad signaling, 
decreased expression and activity of contractile molecules (via MYPT1 for effects 
on MLC), and altered stress-related signaling (e.g., of the MAPKs p38 and ERK1/2) 
likely due to altered hemodynamic stress sensing through cytoskeleton/integrin/
extracellular matrix links. Increased TGF-β may be a compensatory response to 
diminished p-Smad2 signaling and/or a direct effect of altered mechanical stress. 
Additional stress-induced mediators may include reactive oxygen species and 
cytokines as found in other models of arterial remodeling (45). Paracrine effects 
(blue arrows) by secreted soluble molecules from medial cells activate adventi-
tial fibroblasts, leading to increased collagen accumulation, growth factor produc-
tion (e.g., IGF1), and fibroblast proliferation. Adventitial thickening may represent a 
reparative “injury” response and contribute to mural integrity. Reciprocal paracrine 
effects (blue arrows) on medial cells by adventitial-derived mediators contribute to 
increased mTOR signaling and SMC proliferation that exacerbate stress-related 
responses. The outcome of these transcompartmental interactions is maladaptive 
cellular and extracellular matrix remodeling; disease manifests as aortic dilatation 
and/or dissection. We tested this hypothesis with several pharmacological and 
blocking antibody reagents (red font), all of which modulated the phenotype. Addi-
tional studies are required to validate the concept of altered stress sensing after 
Tgfbr2 disruption as recently reported for Acta2-deficient mice in which loss of SMA 
leads to increased focal adhesion kinase signaling resulting in MAPK activation and 
autonomous SMC proliferation (30). Possible further interactions with endothelial 
cells and circulating/resident leukocytes were not considered.
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in Shprintzen-Goldberg syndrome (58). Indeed, even in our work, 
the intense fibroproliferative response of the vessel wall and the 
increase in production of TGF-β ligands and output of TGF-β–
responsive genes suggest that increased TGF-β signaling may con-
tribute to disease manifestations. This extends to the aortic media, 
given the potential for incomplete efficiency of tamoxifen-induced 
recombination, as is notable in the mice with targeting of both 
Tgfbr2 and Fbn1. The bottom line is that a productive balance in 
signaling among vascular cells, cell types, and compartments must 
be achieved for maximal therapeutic gain (59, 60).
In summary, our work addresses previously unanswered ques-
tions regarding the role of TGF-β in homeostasis of the postna-
tal arterial wall and underscores the context-dependent effects of 
TGF-β in aortic disease. In addition to overactivity and dysregu-
lation of canonical versus noncanonical pathways, a loss of basal 
TGF-β signaling in smooth muscle also causes aortic dilatation 
and dissection. Caution is warranted in the use of potent TGF-β 
antagonists for aortic aneurysms that may oversuppress signal-
ing across multiple mural cell types, particularly in children with 
growing aortas analogous to those of our postweanling animals. A 
mitigating strategy may be cotreatment with mTOR inhibitors that 
prevent vascular pathology arising from absent TGF-β responses.
Methods
Mice. Tgfbr2f/f mice (21) were obtained from H.L. Moses (Vanderbilt Universi-
ty, Nashville, Tennessee, USA). Myh11-CreERT2 mice (22) and Fbn1C1039G/+ mice 
(17) have been previously described. Gt(ROSA)26Sortm4(ACTB–tdTomato,–EGFP)Luo/ 
J (mT/mG) mice (23) were purchased from Jackson Laboratory. All strains 
had been backbred onto a C57BL/6 background for more than 8 genera-
tions. Male mice were euthanized at various ages for analysis (the bacterial 
artificial chromosome containing Myh11-CreERT2 inserted on the Y chromo-
some and female mice do not express the construct).
Animal treatment. Cre-Lox recombination was induced by tamoxifen 
(Sigma-Aldrich) at 1 mg/d i.p. for 5 days starting at various ages ver-
sus vehicle (corn oil) alone. Certain animals were treated with BrdU 
(Sigma-Aldrich) at 1 mg s.c. every other day (q.o.d.) between 4 and 6 weeks 
of age, ML-7 (Enzo) at 73 μg/d s.c. constant infusion via implantable pump 
between 4 and 6 weeks of age, rapamycin (Calbiochem) at 2 mg/kg/d i.p. 
every day (q.d.) between 3 and 7 weeks of age with a final dose 24 hours 
before euthanasia, neutralizing antibody to IGF1 (clone 126002, R&D 
Systems) at 125 μg/d i.p. q.o.d. between 4 and 6 weeks of age with a final 
dose 6 hours before euthanasia, and neutralizing antibody to TGF-β1, -2, 
-3 (clone 1D11.16.8, BioXCell) at 250 μg/d i.p. q.o.d. between 4 and 6 or 4 
and 8 weeks of age with a final dose 6 hours before euthanasia. The in vivo 
efficacy of the TGF-β blocking antibody has been previously validated (20).
Tissues. We analyzed the thoracic aorta since it was the primary site of overt 
pathology. Histology, immunohistochemistry, fluorescence microscopy, 
Western blotting, and quantitative RT-PCR were performed in the ascending 
aorta or an equal length segment of proximal descending aorta with similar 
results. The aortic root (from the aortic valve to the coronary arteries) was 
not dissected from the heart and was not included in the analyses.
Cells. Thoracic aortas were predigested for 5 minutes at 37°C in HBSS 
solution containing 1 mg/ml collagenase type A to promote sharp removal 
of the adventitia under a dissecting microscope. The denuded vessels were 
transferred into 2 to 3 ml HBSS solution containing 2 mg/ml collagenase 
type A and 0.5 mg/ml elastase and incubated at 37°C for 30 minutes while 
the digest was titrated with a pipette every 5 to 10 minutes. Digestion was 
stopped with growth medium, the mixture was centrifuged, and the cells 
were resuspended in Claycomb medium (Sigma-Aldrich) supplemented 
with 10% fetal bovine serum (Invitrogen) and cultured in T25 flasks in a 
intermediaries contribute to bidirectional signaling between the 
vascular layers, e.g., reactive oxygen species and cytokines (45, 46). 
The importance of the adventitia in vascular disease is increas-
ingly being recognized, and a greater understanding of inflam-
mation, fibroblast activation, and resident precursor cell niches in 
this compartment have contributed to an integrated view of vessel 
layer functions in vascular remodeling (47, 48).
Our finding of a protective role for basal TGF-β signaling in 
Fbn1C1039G/+ mice suggests that the beneficial effects of systemic 
TGF-β neutralization previously seen in the same model may 
accrue from effects on cell types other than SMCs (17). It is pos-
sible that partial inhibition of excess signaling in the media (due 
to limited antibody penetration into this avascular compartment) 
is not equivalent to complete ablation of resting TGF-β activity 
in SMCs. An important difference is that the vascular phenotype 
is restricted to the aortic root and proximal ascending aorta in 
mouse models of Marfan syndrome (17, 20), whereas disease mani-
festation, signaling changes, and expression differences are pres-
ent throughout the thoracic aorta after Tgfbr2 disruption, albeit 
more pronounced in the ascending aorta. Our results are seem-
ingly similar to previous observations that Tgfb2 and Smad4 hap-
loinsufficiency, expected to attenuate TGF-β signaling, increase 
aortic size and mortality of Fbn1C1039G/+ mice (13, 20). However, in 
those studies, TGF-β signaling was paradoxically activated in aor-
tic tissues in vivo. Although Tgfbr2 exon2 deletion is not a model 
for kinase-mutant receptors in Loeys-Dietz syndrome, the similar 
medial degeneration in both situations suggests that either defi-
cient or excess TGF-β signaling may disrupt SMC homeostasis. 
There are several examples of context-dependent roles of TGF-β in 
disease pathogenesis, such as either gain or loss of signaling in car-
cinoma cells promoting metastasis (49) or resulting in heterotaxy 
and congenital heart disease (50). In support of a protective role in 
arterial disease, TGF-β prevents aortic dilatation in various murine 
models of immunomediated vascular remodeling (51–54) and pro-
tects against immunologic injury of SMCs in experimental human 
systems of arteriosclerosis (55, 56). Specifically, diminished TGF-β 
responses in T cells of Smad3-deficient mice result in transmural 
inflammation of the aorta with aneurysm rupture, and the vascu-
lar phenotype is replicated in WT animals by adoptive transfer of 
Smad3–/– bone marrow or CD4+ T cells (57).
While this work implies the need for caution when considering 
therapeutic use of nonspecific and potent TGF-β antagonists for 
aortic diseases, a number of considerations preclude immediate 
generalization of results made using models with a cell type– 
specific abrogation of TGF-β signaling to patients and mouse 
models with heterozygous loss-of-function mutations in genes 
encoding effectors of TGF-β signaling. Given that all aortic cell 
types in the latter group retain signaling potential, the requisites 
for paracrine overdrive of TGF-β signaling in response to exces-
sive ligand production are maintained, including in the aortic 
media. In this light, it is notable that both mice and people with 
heterozygous mutations in the genes encoding fibrillin-1, TβRI, 
TβRII, Smad3, and TGF-β2 show enhanced Smad-dependent 
TGF-β signaling in the aortic media in association with postnatal 
aneurysm progression and dissection (8–20) and that phenotypic 
rescue in mice with agents such as losartan correlates with a reduc-
tion in TGF-β signaling in aortic SMCs (17). More recently, it was 
shown that loss-of-function mutations in the gene encoding the 
prototypical TGF-β repressor SKI, a perturbation predicted and 
observed to increase TGF-β signaling, cause aortic root aneurysm 
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p-myosin phosphatase target subunit-1 (p-MYPT1), p-AKT (Thr308), 
p-S6K, S6K, p-S6, S6 (all from Cell Signaling), ERK1/2 (Santa Cruz Bio-
technology Inc.), SMA, SM22, SMMHC (all from Abcam), and β-actin 
(Sigma-Aldrich), followed by horseradish peroxidase–conjugated sec-
ondary antibodies (Jackson ImmunoResearch). A different p-Smad2 
antibody (ser465/467; Millipore) was used in certain experiments after 
a batch change in the initial reagent. Bound antibody was detected with 
Western Lightning Plus-ECL (PerkinElmer).
RT-PCR. Crushed aortic tissue or scraped cells were immersed in RLT 
lysis buffer (QIAGEN) and vigorously vortexed, and total RNA was iso-
lated using RNeasy Mini Kits and DNA digestion kits (QIAGEN) according 
to the manufacturer’s protocol. RT with random hexamer and oligo-dT 
primers was performed according to the Multiscribe RT system proto-
col (Applied Biosystems). PCR was performed using cDNA, PCR Redmix 
(Sigma-Aldrich), and primers specific for Tgfbr2 exon2 (forward 5′-TTAA-
CATGATGTCATGGCCAGCG-3′ and reverse 5′-AGACTTCATGCG-
GCTTCTCACAGA-3′); the solution was separated by 1.5% agarose gel 
using 18S RNA as a control. Real-time quantitative RT-PCR reactions were 
prepared with TaqMan PCR Master Mix and predeveloped assay reagents 
from Applied Biosystems. Samples were analyzed on an iCycler (Bio-Rad 
Laboratories). RNA samples processed without the RT enzyme were used 
as negative controls. The expression level of each transcript was normalized 
to that of Hprt1 as log2 (reference gene – gene of interest quantification 
cycle). We confirmed stable expression of Hprt1 under our experimental 
conditions with significant correlation (r = 0.9529–0.9912, P < 0.0001, 
Pearson test) to 2 other reference transcripts of Gapdh and Actb in a subset 
of in vitro (n = 18) and in vivo (n = 18) samples.
Laser capture microdissection. Aortas were cut into 5-μm sections and 
placed on charged slides prior to fixation in 70% ethanol. The slides were 
stained with H&E, rinsed in an ethanol gradient, and dehydrated in a 
xylene mixture. The adventitia and media were sequentially procured 
using a Pixcell laser capture microscope (Arcturus Engineering) and 
transferred to CapSure films (Arcturus Engineering); RNA was isolated 
for quantitative RT-PCR.
Microarray analysis. Ascending aortas were harvested from 6-week-old 
Myh11-CreERT2.Tgfbr2f/f and Fbn1C1039G/+.Myh11-CreERT2.Tgfbr2f/f littermates 
treated with vehicle or tamoxifen at 4 weeks of age (n = 3 in each of the 4 
groups). Preparation of sscDNA and hybridization to the mouse GeneChip 
set (1.0 ST Array) were performed according to the manufacturer’s proto-
col (Affymetrix). The stained chips were read and analyzed with GeneChip 
Scanner 3000 (Affymetrix). Expression intensities were quantified and 
compared using Partek Genomics Suite v6.4 (Partek Inc.) with robust 
multi-array average for normalization and fold-change calculations. Com-
parisons of log2-transformed data were by unpaired t test after filtering for 
false discovery rate to correct for multiple comparisons. For the purposes 
of this study, gene expression differences that differed by more than 2-fold 
relative to comparison groups with P values of less than 0.05 were consid-
ered significant. The primary microarray data have been deposited in the 
Gene Expression Omnibus (GSE36778).
Flow cytometry. GFP+ SMCs were labeled with biotinylated antibody to 
the extracellular domain of TβRII (R&D Systems) and APC-conjugated 
anti-biotin antibody or isotype-matched, irrelevant IgG. Analysis was per-
formed using a FACSCalibur and FlowJo 7.0 software.
Collagen gels. GFP+ SMCs were suspended at 2.5 × 105 cells/ml in type I 
collagen at 2.5 mg/ml (BD Biosciences) with 10 μl/ml 1N NaOH. The 
mixture was poured into 24-well tissue culture plates (1 ml/2 cm2 well) 
that were precoated with 1% gelatin and allowed to polymerize in a 5% 
CO2 incubator at 37°C for 30 minutes; 1 ml of growth medium was 
added. Gel contraction was assessed at 72 hours by scanning the plates 
and determining surface area using NIH ImageJ.
CO2 incubator at 37°C. On reaching confluence, the cells were detached 
with trypsin, and GFP+ SMCs were sorted under sterile conditions using a 
FACSCalibur (BD Biosciences). The cells were serially expanded, and pas-
sages 3–6 were used for experiments. Signaling studies were performed 
after resting the SMCs in serum-free DMEM medium for 24 hours fol-
lowed by treatment with TGF-β1, TGF-β2, TGF-β3, IGF1 (R&D Systems), 
and/or rapamycin (Calbiochem) at the indicated doses and times.
Vascular studies. Animals were anesthetized with isoflurane. B-mode ultra-
sound images of the ascending aorta in transverse and longitudinal planes 
were obtained using a Vevo 770 system (VisualSonics). For invasive hemody-
namic analysis, the aorta was catheterized via the carotid artery using a 1.4-Fr 
Mikro-Tip pressure catheter (Millar Instruments), and blood pressure mea-
surements were obtained using a PowerLab system (ADInstruments).
Histology. The vasculature was perfusion-fixed with 4% paraformaldehyde 
(PFA) via the left ventricle at 80 mmHg. For macroscopic examination, the 
aorta was exposed in situ and imaged with a dissecting microscope (Olym-
pus). For histology, the aorta was excised and embedded in paraffin, and 
5 μm-thick transverse sections were stained with H&E, elastin–Van Gieson 
(EVG), Masson’s trichrome, and Sirius red using standard techniques. The 
histological sections were analyzed using ImageJ software (http://rsbweb.
nih.gov/ij/) by outlining the arterial compartment perimeters to calculate 
mean area/thickness and by assessing staining intensity as pixel counts. 
Hematoxylin-stained nuclei within the media were counted in PFA-fixed, 
OCT-embedded sections and averaged from 3 high power fields.
Immunohistochemistry. Immunolabeling of 5 μm-thick, paraffin-embed-
ded aorta sections was performed with primary antibodies to BrdU 
(Abcam), CD45 (Abnova), TER119 (R&D Systems), SMA (Sigma-Aldrich), 
p-S6K, p-Smad2 (ser465/467), p-MLC (all from Cell Signaling), or isotype-
matched, irrelevant IgG. Binding of secondary antibody (Jackson Immuno-
Research) was detected with vectastain ABC reagent and AEC peroxidase 
substrate kits (Vector Laboratories), counterstained with hematoxylin, and 
imaged using an Axioskop2 Plus microscope (Carl Zeiss MicroImaging). 
Additionally, PFA-fixed, OCT-embedded tissue sections were incubated 
with CD45 antibody (BD Biosciences). Cultured cells were fixed with 4% 
PFA, permeabilized with 0.1% Triton X-100, and denatured with 2 M HCL 
for 10 minutes prior to BrdU antibody labeling.
Fluorescence microscopy. For studies of reporter mice, aortas were perfused 
with cold 4% PFA in 0.1 M PBS (Sigma-Aldrich), fixed overnight in 4% PFA 
at 4°C, cryoprotected in 15% sucrose for 6 to 8 hours at 4°C, and embed-
ded in OCT (Tissue-Tek), and 5-μm–thick sections were obtained using 
a Leica cryostat. For immunofluorescence analysis, 5-μm–thick, paraffin-
embedded aorta sections were labeled with antibodies to Ki-67 (Abcam), 
p-MLC, p-Smad2 (ser465/467), p-ERK1/2 (Thr202/Tyr204) (all from Cell 
Signaling), or isotype-matched, irrelevant IgG. Detection of primary anti-
bodies was visualized with Alexa Fluor 594–conjugated goat anti-rabbit 
IgG (Invitrogen). FITC-conjugated anti-SMA (Sigma-Aldrich) was added 
for double staining of SMCs. Sections were mounted with ProLong Gold 
antifade reagent with DAPI (Invitrogen) and imaged using an Axiovert 
200M microscopy system with AxioVision 4.6 software (Carl Zeiss Micro-
Imaging). Alternatively, SMCs cultured on sterile glass coverslips were 
fixed and permeabilized, as for immunohistochemistry, prior to incuba-
tion with antibodies.
Immunoblotting. Protein was extracted from aortas and SMCs using 
RIPA lysis buffer containing a protease inhibitor cocktail (Thermo Scien-
tific) with PhosSTOP (Roche) and boiled in SDS sample buffer for 6 min-
utes. Equal amounts of protein per sample were separated by SDS-PAGE, 
transferred electrophoretically to a nitrocellulose membrane (Bio-Rad 
Laboratories), and blotted with antibodies against TβRII extracellular 
domain (R&D Systems), p-Smad2 (ser465/467, clone 138D4), Smad2 
(clone L16D3), p-p38 (Thr180/Tyr182), p38, p-ERK1/2, p-MLC, MLC, 
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